A Study of Enterorenal Syndrome Assessed by Gastrointestinal Ultrasound Combined with Renal Artery Resistance Index
Launched by ZHANGZHOU MUNICIPAL HOSPITAL · Jul 11, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain ultrasound tests can help doctors better understand the relationship between gut and kidney health in patients with sepsis, which is a serious condition often caused by infections in the abdomen. The researchers will compare ultrasound results related to the stomach and intestines, as well as blood flow in the kidneys, to see how these factors relate to patient survival. By identifying changes in these areas early, the goal is to improve treatment decisions and increase the chances of recovery for those affected by this condition.
To participate in this study, patients must be in the intensive care unit (ICU) with sepsis or septic shock due to an abdominal infection. Unfortunately, those with severe injuries, advanced cancer, kidney failure, or who are pregnant cannot take part. Participants can expect to undergo ultrasound examinations, which are non-invasive and painless, to help gather important information for their care. This research aims to provide valuable insights that could lead to better outcomes for patients with sepsis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with intra-abdominal infections
- • Patients with sepsis or septic shock
- Exclusion Criteria:
- • Patients with open chest or abdominal injury
- • Patients with advanced tumor
- • Patients with uremia
- • Pregnant women
About Zhangzhou Municipal Hospital
Zhangzhou Municipal Hospital is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. With a commitment to improving patient outcomes and enhancing medical knowledge, the hospital collaborates with various stakeholders to conduct high-quality clinical studies across diverse therapeutic areas. Equipped with state-of-the-art facilities and a team of experienced healthcare professionals, Zhangzhou Municipal Hospital fosters an environment of excellence in patient care and research, aiming to contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhangzhou, Fujian, China
Patients applied
Trial Officials
Hui Jiang, Dr.
Principal Investigator
the Ethnics Committee of Zhangzhou Municipal Hospital of Fujian Province
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported